University of California, San Diego (UC San Diego, UCSD)

Autophagy inhibition promotes SNCA/alpha-synuclein release and transfer via extracellular vesicles with a hybrid autophagosome-exosome-like phenotype (2017) Minakaki G, Menges S, Kittel A, Emmanouilidou E, Schäffner I, Barkovits K, Bergmann A, et al. Journal article Oligomer-prone E57K-mutant alpha-synuclein exacerbates integration deficit of adult hippocampal newborn neurons in transgenic mice (2017) Regensburger M, Schreglmann SR, Stoll S, Rockenstein E, Loskarn S, Xiang W, Masliah E, Winner B Journal article Intestinal fungi contribute to development of alcoholic liver disease (2017) Yang AM, Inamine T, Hochrath K, Chen P, Wang L, Llorente C, Bluemel S, et al. Journal article Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy (2017) Levin A, Tonelli M, Bonventre J, Coresh J, Donner JA, Fogo AB, Fox CS, et al. Journal article, Review article Wnt9a Is Required for the Aortic Amplification of Nascent Hematopoietic Stem Cells (2016) Grainger S, Richter J, Palazon RE, Pouget C, Lonquich B, Wirth S, Grassme KS, et al. Journal article Sialic Acid-Binding Immunoglobulin-like Lectin G Promotes Atherosclerosis and Liver Inflammation by Suppressing the Protective Functions of B-1 Cells (2016) Gruber S, Hendrikx T, Tsiantoulas D, Ozsvar-Kozma M, Goederle L, Mallat Z, Witztum JL, et al. Journal article Long-Term (156-Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of 3 Phase III, Randomized, Controlled Trials (2016) Mease PJ, Gladman DD, Gomez-Reino JJ, Hall S, Kavanaugh A, Lespessailles E, Schett G, et al. Conference contribution Apremilast Treatment and Long-Term (156-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Analysis of a Large Database of 3 Phase III, Randomized, Controlled Trials (2016) Gladman DD, Kavanaugh A, Gomez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, Lespessailles E, et al. Conference contribution APREMILAST, AN ORAL PHOSPHODIESTERASE-4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (104-WEEK) IMPROVEMENTS IN ENTHESITIS AND DACTYLITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED RESULTS FROM THREE PHASE III RANDOMIZED CONTROLLED TRIALS (2016) Gladman DD, Kavanaugh A, Adebajo AO, Gomez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, et al. Conference contribution Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-term (104-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase III, Randomized, Controlled Trials (2016) Gladman D, Kavanaugh A, Adebajo A, Gomez-Reino J, Wollenhaupt J, Cutolo M, Schett G, et al. Conference contribution